View Older Stories View More Recent Stories

Oct 2, 2019 06:31AM Merck (MRK) Announces FDA Accepts Two Applications for its DIFICID to Treat Children with Clostridium difficile Infections
Oct 2, 2019 06:30AM FDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections
Oct 1, 2019 06:55AM Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29
Sep 30, 2019 10:32AM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA More Than Doubled Median rPFS in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care
Sep 30, 2019 10:30AM LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months)
Sep 30, 2019 06:55AM Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Sep 30, 2019 06:49AM Merck (MRK) Announces Pivotal RESTORE-IMI 2 Phase 3 Study of RECARBRIO in HABP/VABP Met Primary Endpoint
Sep 30, 2019 06:45AM Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint
Sep 30, 2019 06:37AM Merck's (MRK) KEYTRUDA Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage TNBC
Sep 29, 2019 10:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Nega
Sep 29, 2019 02:30AM Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
Sep 28, 2019 10:30AM LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer
Sep 27, 2019 02:00AM New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Sep 20, 2019 08:11AM Merck KGaA, Pfizer (PFE) Announce CHMP Adopts Positive Opinion for BAVENCIO Plus Axitinib for First-Line Treatment of Patients with Advanced RCC
Sep 20, 2019 08:10AM CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Sep 20, 2019 06:46AM Merck's (MRK) PIFELTRO and DELSTRIGO Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
Sep 20, 2019 06:45AM Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically
Sep 18, 2019 06:21AM Merck (MRK) Announces FDA Approves KEYTRUDA plus LENVIMA Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Sep 17, 2019 05:56PM FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Sep 17, 2019 06:46AM Merck (MRK) Announces FDA Accepts its BLA and Grants Priority Review for V920 Vaccine for Ebola Zaire Virus
Sep 17, 2019 06:45AM FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
Sep 10, 2019 08:00AM Merck Announces First Nine “Safer Childbirth Cities” Committed to Reducing Maternal Deaths and Narrowing Disparities in the US
Sep 10, 2019 06:48AM Merck (MRK) Pooled Analysis Continues to Show its KEYTRUDA in Combination with Chemotherapy Improved OS for Patients with Advanced NSCLC
Sep 10, 2019 06:45AM Pooled Analysis Continues to Show Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Ad
Sep 9, 2019 06:48AM Merck (MRK) Announces Pivotal New Data from its Broad Oncology Portfolio at ESMO
Sep 9, 2019 06:45AM Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
Sep 5, 2019 06:45AM Merck to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
Sep 4, 2019 06:51AM Merck (MRK) announces EC Approves its KEYTRUDA in Combination with Inlyta as First-Line Treatment for Patients with Advanced RCC
Sep 4, 2019 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)
Aug 22, 2019 06:45AM Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer
Aug 19, 2019 08:00AM MilliporeSigma Granted 20 CRISPR Patents Total Worldwide
Aug 14, 2019 06:55AM LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer
Aug 7, 2019 04:39PM Merck Announces Leadership Changes to Investor Relations Team
Aug 7, 2019 06:55AM LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
Aug 7, 2019 06:55AM LYNPARZA® (olaparib) Phase 3 PROfound Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
Jul 31, 2019 06:46AM Merck (MRK) Announces FDA Approves New Monotherapy Indication for its KEYTRUDA
Jul 31, 2019 06:45AM FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab)
Jul 30, 2019 06:45AM Merck Announces Second-Quarter 2019 Financial Results
Jul 29, 2019 04:58PM Merck (MRK) Receives Positive EU CHMP Opinion for ZERBAXA 3g Dose for Treatment of Adults with HAP, Including VAP
Jul 29, 2019 04:05PM Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia
Jul 29, 2019 06:56AM Merck (MRK) in Combination with Chemotherapy Met Primary Endpoint of pCR in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with TNBC
Jul 29, 2019 06:55AM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative
Jul 29, 2019 06:31AM Merck (MRK) Announces EMA Adopts Positive Opinion for KEYTRUDA in Combination with Inlyta as First-Line Treatment for Advanced RCC
Jul 29, 2019 06:30AM European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
Jul 24, 2019 11:03AM Merck (MRK) Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir at IAS
Jul 24, 2019 11:00AM Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019
Jul 23, 2019 12:54PM Merck Announces Fourth-Quarter 2019 Dividend
Jul 23, 2019 11:01AM Merck (MRK) Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir
Jul 23, 2019 11:00AM Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant
Jul 23, 2019 06:48AM Merck (MRK), Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA plus LENVIMA Combination Treatment
View More Recent Stories View Older Stories